Diatech files INDs for two peptides

Article

Peptide-based imaging agent developer Diatech has filed two investigationalnew drug (IND) applications with the Food and Drug Administrationfor technetium-99m-labeled radiopharmaceuticals. Diatech, of Londonderry,NH, reported the news this month. The

Peptide-based imaging agent developer Diatech has filed two investigationalnew drug (IND) applications with the Food and Drug Administrationfor technetium-99m-labeled radiopharmaceuticals. Diatech, of Londonderry,NH, reported the news this month.

The first agent, Tc-99m P748, is for the rapid detection ofpulmonary embolism. The peptide binds to a glycoprotein receptorlocated at activated platelets involved in blood clots. The secondagent, Tc-99m P829, is a somatostatin peptide for localizing canceroustumors. Diatech claims that a study presented at last year's RadiologicalSociety of North America meeting indicated that an agent closelyrelated to P829 may have better target to non-target ratios comparedto OctreoScan, a peptide-based imaging agent released by MallinckrodtMedical last year (SCAN 6/15/94).

The IND filings bring to five the number of Diatech productsin clinical trials, according to Diatech president Richard Dean.Diatech is also developing peptide-based radiopharmaceuticalsfor the detection of deep-vein thrombosis and atherosclerosisand for the treatment of bone metastases.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.